病毒学
乙型肝炎病毒
体外
病毒
丙型肝炎病毒
临床试验
病毒复制
细胞培养
医学
乙型肝炎
生物
病理
遗传学
作者
Qi Huang,Dawei Cai,Ran Yan,Lichun Li,Yu Zong,Lida Guo,Alexandre Mercier,Yi Zhou,Ariel Tang,Kirk R. Henne,Richard J. Colonno
摘要
ABI-H0731, a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity in chronic hepatitis B (CHB) patients in a phase 1b clinical trial and is currently being further evaluated in phase 2 clinical trials. Here, we report the preclinical profile of ABI-H0731. In in vitro cell culture systems (HepG2-derived cell lines HepAD38 and HepG2-NTCP and primary human hepatocytes [PHHs]), ABI-H0731 exhibited selective inhibition of HBV DNA replication (50% effective concentration [EC 50 ] from 173 nM to 307 nM).
科研通智能强力驱动
Strongly Powered by AbleSci AI